As we keep stating, we are very proud to be an affiliate of The Bonnie J. Addario Lung Cancer Foundation and to be raising funds for their lung cancer research arm, ALCMI.
What you will see and hear in the video below is a big reason why. Here is Bonnie's story. Please take a moment an watch this video.
www.twitter.com/thedayifoundout
www.twitter.com/bonniejaddario
www.twitter.com/forjoan
Showing posts with label ALCMI. Show all posts
Showing posts with label ALCMI. Show all posts
Friday, August 12, 2011
Tuesday, July 5, 2011
Thursday, June 30, 2011
Lung Cancer Controversy Extinguised: CT Scan Versus X-Ray: CT Scan Wins!
Originally published by The Bonnie J. Addario Lung Cancer Foundaton (BJALCF) on June 30th, 2011. The Joan Gaeta Lung Cancer Fund is a proud affiliate of BJALCF, raising money for its research institute, ALCMI.San Francisco-June 29, 2011–The New England Journal of Medicine’s (NEJM) headline today read, “Reduced Lung Cancer Mortality with Low-Dose Computed Tomographic CT Screening,” ending a long controversy over the use of an existing but underutilized early detection tool for those at risk for Lung Cancer. Preliminary results of the National Lung Screening Trial (NLST) were first released on November 4, 2010 and confirmed today. The study of more than 53,000 people who either once smoked or currently smoked found there were 20 percent fewer deaths among those who underwent annual screening with a scanning procedure known as a low-dose helical computed tomography (CT) compared with those who got standard chest X-rays. Click here to read the full article in NEJM.
The findings were so striking that the National Cancer Institute, which helped sponsor the study, halted the eight-year trial early after a panel of experts notified officials about the clear results of an interim analysis and Dr. Varmus released the preliminary results immediately. “Lung cancer is the leading cause of cancer mortality in the U.S. and throughout the world, so a validated approach that can reduce lung cancer mortality by even 20 percent has the potential to spare very significant numbers of people from the ravages of this disease,” said Varmus.
The long-anticipated results were in concert with what the Bonnie J. Addario Lung Cancer Foundation has advocated since its inception, in March 2006.
Bonnie J. Addario, Founder of BJALCF and ALCMI, commented, “This is fantastic news. We knew this, and generated long overdue attention with our national PUBLIC AWARENESS CAMPAIGN to Demand a CT Scan, and our Comprehensive Lung Cancer Screening Program four years ago, which fueled this conversation. Today’s NLST study results support and confirm our intellectual, scientific, personal and practical mission to significantly increase the survival rate for Lung Cancer for the first time in forty years.”
“This is a landmark study and a landmark day for millions of people at risk for Lung Cancer,” said David Jablons, MD, Professor and Chief of Thoracic Surgery, University of California San Francisco (UCSF) and co-founder of the Bonnie J. Addario Lung Cancer Foundation (BJALCF). “This study vindicates numerous pioneering investigators worldwide who have advocated for the utility and benefit of low-dose spiral CT scans for the early detection of Lung Cancer. The results announced today in the New England Journal of Medicine lay to rest the question of using the low-dose spiral CT scan for the at-risk population. CT scans can save lives. It is our hope that third-party payors and insurers will embrace these results which will lead to more screening, a new standard of care and most important, saving lives.”
Scott Santarella, BJALCF’s President and CEO, former President and CEO of the American Lung Cancer Association in New York and former COO of the Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC), stated, “Today's announcement validates our belief in utilizing the tools available to the lung cancer community to diagnose patients as early as possible because we know it saves lives.”
Bonnie J. Addario is a seven-year Stage IIIB CT-scanned Lung Cancer Survivor. She, BJALCF and ALCMI will be presenting at the International Association for the Study of Lung Cancer (IASLC) 14th Annual World Conference in Amsterdam on July 5, 2011. BJALCF and ALCMI are the only non-profit lung cancer foundations ever to have been invited as guests to present a Satellite Symposium at an IASLC World Conference. The Symposium is entitled, “The Way Forward.”
About the Bonnie J. Addario Lung Cancer Foundation (BJALCF)
BJALCF is THE patient-founded, patient-focused voice relentlessly working to increase the survival of Lung Cancer worldwide through early detection, awareness and funding for research. BJALCF was established in 2006 as a 501(c)(3) non-profit organization and has raised over six million dollars for Lung Cancer Research. Contact: Sheila Von Driska, Executive Director, sheila@lungcancerfoundation.org 415.357.1278
About the Addario Lung Cancer Medical Institute (ALCMI)
ALCMI was established in 2008 as a 501(c)(3) non-profit organization with the ultimate goal of significantly impacting survival by catalyzing and accelerating discovery of new and more effective treatment options for all lung cancer patients.
Contact: Steven Young, President, syoung@alcmi.net 203.247.9035
About The Joan Gaeta Lung Cancer Fund
A lifelong non-smoker, Joan Gaeta was a devoted wife, teacher, and mother of five. Diagnosed with Lung Cancer in early 2004, she fought a three and a half year battle before succumbing in July of 2007.
During that time, Joan stressed the need for greater awareness of Lung Cancer, the number one cancer killer in the world, which has a very low survival rate and a tragic lack of research funds. She was most passionate about eliminating the stigma of the disease, since lung cancer also strikes non-smokers at a high rate.
The Joan Gaeta Lung Cancer Fund was created in the fall of 2007 as The Joan Gaeta Lung Cancer Foundation by her husband and children to raise awareness of the disease, to educate the public, and to be an advocate for research. We also strive to eliminate the stigma of lung cancer and to support survivors and their loved ones in our local community.
In July of 2010, they re-launched as The Joan Gaeta Lung Cancer Fund benefiting the Addario Lung Cancer Medical Institute. Their ultimate goal remains the same: “to eradicate lung cancer.” By partnering with one significant research initiative, they can make a much greater impact in wiping out lung cancer.
Contact: gaetafund@gmail.com or (404) 987-0792
Thursday, June 16, 2011
Our Cause...
The Joan Gaeta Lung Cancer Fund is a proud affiliate of The Bonnie J. Addario Lung Cancer Foundaton and is honored to help raise money for ALCMI.
Please watch this important video.
Please watch this important video.
Thursday, June 2, 2011
Watch ESPN on June 5th at 10:40am Eastern Time for an Inspiring Story!
*** 6/3 UPDATE: Please note time correction.
*** It will air at 10:40am Eastern on June 5th.
As you know, The Joan Gaeta Lung Cancer Fund is a very proud affiliate of The Bonnie J. Addario Lung Cancer Foundation. Our fundraising efforts support their lung cancer medical institute, ALCMI.
*** It will air at 10:40am Eastern on June 5th.
As you know, The Joan Gaeta Lung Cancer Fund is a very proud affiliate of The Bonnie J. Addario Lung Cancer Foundation. Our fundraising efforts support their lung cancer medical institute, ALCMI.
The documentary is produced by award-winning Benjamin M. Webber and his ESPN Crew. The segment will air again immediately following ESPN's Sunday Night Baseball game.
Friday, April 29, 2011
Biodesix Supports Unique Lung Cancer Initiative (ALCMI)
CASTLE STUDY ENROLLS SUBJECTS
Posted April 29, 2011 on www.bjalcf.org.
BROOMFIELD, Colo., April 28, 2011 /PRNewswire/ — Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as “Alchemy”). The CASTLE (Collaborative Advanced Stage Tissue Lung Cancer) study is recruiting a minimum of 250 subjects over two years among academic and community medical centers in the United States. The study collects biospecimens and data from lung cancer patients in order to facilitate and accelerate the development and delivery of diagnostic tests and treatments tailored to the individual patient. As part of the study, Biodesix is performing VeriStrat® testing on eligible patients and serving as ALCMI’s biorepository for all serum samples collected from CASTLE study subjects for future research. VeriStrat is a serum proteomic test for advanced non-small cell lung cancer patients that helps physicians determine if a patient should receive treatment with a drug called erlotinib.
Biodesix is committed to advancing the field of personalized medicine by developing unique and clinically useful diagnostic tests in oncology. This collaboration is the first of its kind in bringing together leading lung cancer scientists in the U.S. and Europe, patient advocates, and diagnostic laboratories to collect biospecimens with the intent of developing personalized therapies and tests that could improve patient outcomes. “We are pleased to offer the only serum-based testing for the CASTLE study and play an integral role in this collaboration” commented Paul Beresford, Biodesix’ Vice President in charge of the company’s laboratory operations. “We look forward to supporting our ALCMI colleagues in their efforts to accelerate translational medicine in lung cancer and continuing to shift the standard of care toward widespread use of molecular testing in clinical decision-making.”
About NSCLC: As reported by the American Cancer Society, lung cancer is the leading cause of cancer death in the US. NSCLC represents approximately 87% of lung cancer. An estimated 215,000 new cases of lung cancer and 162,000 deaths due to lung cancer occurred in the US in 2008. Treatment options include surgery, radiation therapy, chemotherapy and targeted biological therapies such as bevacizumab (Avastin®) and erlotinib (Tarceva®). Less than 5% of advanced NSCLC patients survive for 5 years, emphasizing the need for improved patient selection to maximize drug efficacy.
About VeriStrat: VeriStrat is a proteomic serum test for patients with advanced NSCLC. The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs). Samples are processed in Biodesix’ CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat has been validated in clinical studies with over 1500 patients. Biodesix is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFRIs. For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.
About Biodesix: Biodesix is a fully integrated molecular diagnostic company developing products that support excellence in clinical decision making and improve patient care. The Company’s goal is to give physicians more information to understand the patient and their disease. Understanding the clinically meaningful information contained within each patient’s molecular profile leads to better care and better outcomes. The Company’s unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles that can be used to better characterize the patient and their disease. Biodesix collaborates with investigators to address key clinical questions, and partners with biotechnology and pharmaceutical companies for development of companion diagnostics and improved targeting of therapies in clinical trials. For more information about Biodesix, please visit the Company’s website at www.Biodesix.com
This press release contains statements that are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company’s inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company’s financial resources will be insufficient to meet the Company’s business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.
SOURCE Biodesix
Posted April 29, 2011 on www.bjalcf.org.
BROOMFIELD, Colo., April 28, 2011 /PRNewswire/ — Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as “Alchemy”). The CASTLE (Collaborative Advanced Stage Tissue Lung Cancer) study is recruiting a minimum of 250 subjects over two years among academic and community medical centers in the United States. The study collects biospecimens and data from lung cancer patients in order to facilitate and accelerate the development and delivery of diagnostic tests and treatments tailored to the individual patient. As part of the study, Biodesix is performing VeriStrat® testing on eligible patients and serving as ALCMI’s biorepository for all serum samples collected from CASTLE study subjects for future research. VeriStrat is a serum proteomic test for advanced non-small cell lung cancer patients that helps physicians determine if a patient should receive treatment with a drug called erlotinib.
Biodesix is committed to advancing the field of personalized medicine by developing unique and clinically useful diagnostic tests in oncology. This collaboration is the first of its kind in bringing together leading lung cancer scientists in the U.S. and Europe, patient advocates, and diagnostic laboratories to collect biospecimens with the intent of developing personalized therapies and tests that could improve patient outcomes. “We are pleased to offer the only serum-based testing for the CASTLE study and play an integral role in this collaboration” commented Paul Beresford, Biodesix’ Vice President in charge of the company’s laboratory operations. “We look forward to supporting our ALCMI colleagues in their efforts to accelerate translational medicine in lung cancer and continuing to shift the standard of care toward widespread use of molecular testing in clinical decision-making.”
About NSCLC: As reported by the American Cancer Society, lung cancer is the leading cause of cancer death in the US. NSCLC represents approximately 87% of lung cancer. An estimated 215,000 new cases of lung cancer and 162,000 deaths due to lung cancer occurred in the US in 2008. Treatment options include surgery, radiation therapy, chemotherapy and targeted biological therapies such as bevacizumab (Avastin®) and erlotinib (Tarceva®). Less than 5% of advanced NSCLC patients survive for 5 years, emphasizing the need for improved patient selection to maximize drug efficacy.
About VeriStrat: VeriStrat is a proteomic serum test for patients with advanced NSCLC. The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs). Samples are processed in Biodesix’ CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat has been validated in clinical studies with over 1500 patients. Biodesix is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFRIs. For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.
About Biodesix: Biodesix is a fully integrated molecular diagnostic company developing products that support excellence in clinical decision making and improve patient care. The Company’s goal is to give physicians more information to understand the patient and their disease. Understanding the clinically meaningful information contained within each patient’s molecular profile leads to better care and better outcomes. The Company’s unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles that can be used to better characterize the patient and their disease. Biodesix collaborates with investigators to address key clinical questions, and partners with biotechnology and pharmaceutical companies for development of companion diagnostics and improved targeting of therapies in clinical trials. For more information about Biodesix, please visit the Company’s website at www.Biodesix.com
This press release contains statements that are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company’s inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company’s financial resources will be insufficient to meet the Company’s business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.
SOURCE Biodesix
Tuesday, March 29, 2011
THE JOAN GAETA LUNG CANCER FUND RAISES $15,000 FOR ALCMI
4th Annual “Dancing for Joan” Gala A Huge Success
FOR IMMEDIATE RELEASE
ATLANTA, GA. March 29, 2011: For the fourth consecutive year, The Joan Gaeta Lung Cancer Fund’s Annual “Dancing for Joan” event was a huge success, committing $15,000 to international Lung Cancer research through the Addario Lung Cancer Medical Institute (ALMCI).
CNN Anchor Nancy Grace served again this year as the evening’s emcee for a crowd of more than 200 people who came together on February 26, 2011 at the Pavillion of East Cobb in Marietta, Georgia.
Also returning this year was the event's Honorary Chairman Dr. Paul Scheinberg, Chief of Staff at Saint Joseph's Hospital in Atlanta. This year's annual Hummingbird Award for Dedication was presented to Alice Kerber, RN - also of Saint Joseph's Hospital - for her tireless work as a Lung Cancer advocate and oncology navigator.
“We are very excited about the partnership with ALMCI and for what our annual event was able to accomplish,” says Joe Gaeta, president of The Joan Gaeta Lung Cancer Fund, and son of the late Joan Gaeta, in whose memory the organization was founded. “We are confident that our supporter’s generous donations will make a deep and immediate impact with ALCMI.”
In July of 2010, the Gaetas announced their formal partnership with The Addario Lung Cancer Medical Institute, committing 85 percent of their net proceeds to the excellent work ALCMI is doing. Remaining funds are used in metro Atlanta for an annual awareness campaign and to sponsor the Lung Cancer support group.
“We are deeply thankful to the Gaeta Family for their commitment to ending Lung Cancer in Joan's memory,” says Bonnie J. Addario, founder. “It is with partners like the Gaeta Fund that will allow ALCMI to begin to raise the 'curability' of Lung Cancer in a significant way.”
About The Joan Gaeta Lung Cancer Fund
A lifelong non-smoker, Joan Gaeta was a devoted wife, teacher, and mother of five. Diagnosed with Lung Cancer in early 2004, she fought a three and a half year battle before succumbing in July of 2007.
During that time, Joan stressed the need for greater awareness of Lung Cancer, the number one cancer killer in the world, which has a very low survival rate and a tragic lack of research funds. She was most passionate about eliminating the stigma of the disease, since lung cancer also strikes non-smokers at a high rate.
The Joan Gaeta Lung Cancer Fund was created in the fall of 2007 as The Joan Gaeta Lung Cancer Foundation by her husband and children to raise awareness of the disease, to educate the public, and to be an advocate for research. We also strive to eliminate the stigma of lung cancer and to support survivors and their loved ones in our local community.
In July of 2010, they re-launched as The Joan Gaeta Lung Cancer Fund benefiting the Addario Lung Cancer Medical Institute. Their ultimate goal remains the same: “to eradicate lung cancer.” By partnering with one significant research initiative, they can make a much greater impact in wiping out lung cancer.
www.forjoan.org
About The Addario Lung Cancer Medical Institute (ALCMI)
The Addario Lung Cancer Medical Institute (ALCMI) is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for Lung Cancer patients.
For more information Contact:
www.alcmi.net
FOR IMMEDIATE RELEASE
ATLANTA, GA. March 29, 2011: For the fourth consecutive year, The Joan Gaeta Lung Cancer Fund’s Annual “Dancing for Joan” event was a huge success, committing $15,000 to international Lung Cancer research through the Addario Lung Cancer Medical Institute (ALMCI).
CNN Anchor Nancy Grace served again this year as the evening’s emcee for a crowd of more than 200 people who came together on February 26, 2011 at the Pavillion of East Cobb in Marietta, Georgia.
Also returning this year was the event's Honorary Chairman Dr. Paul Scheinberg, Chief of Staff at Saint Joseph's Hospital in Atlanta. This year's annual Hummingbird Award for Dedication was presented to Alice Kerber, RN - also of Saint Joseph's Hospital - for her tireless work as a Lung Cancer advocate and oncology navigator.
“We are very excited about the partnership with ALMCI and for what our annual event was able to accomplish,” says Joe Gaeta, president of The Joan Gaeta Lung Cancer Fund, and son of the late Joan Gaeta, in whose memory the organization was founded. “We are confident that our supporter’s generous donations will make a deep and immediate impact with ALCMI.”
In July of 2010, the Gaetas announced their formal partnership with The Addario Lung Cancer Medical Institute, committing 85 percent of their net proceeds to the excellent work ALCMI is doing. Remaining funds are used in metro Atlanta for an annual awareness campaign and to sponsor the Lung Cancer support group.
“We are deeply thankful to the Gaeta Family for their commitment to ending Lung Cancer in Joan's memory,” says Bonnie J. Addario, founder. “It is with partners like the Gaeta Fund that will allow ALCMI to begin to raise the 'curability' of Lung Cancer in a significant way.”
About The Joan Gaeta Lung Cancer Fund
A lifelong non-smoker, Joan Gaeta was a devoted wife, teacher, and mother of five. Diagnosed with Lung Cancer in early 2004, she fought a three and a half year battle before succumbing in July of 2007.
During that time, Joan stressed the need for greater awareness of Lung Cancer, the number one cancer killer in the world, which has a very low survival rate and a tragic lack of research funds. She was most passionate about eliminating the stigma of the disease, since lung cancer also strikes non-smokers at a high rate.
The Joan Gaeta Lung Cancer Fund was created in the fall of 2007 as The Joan Gaeta Lung Cancer Foundation by her husband and children to raise awareness of the disease, to educate the public, and to be an advocate for research. We also strive to eliminate the stigma of lung cancer and to support survivors and their loved ones in our local community.
In July of 2010, they re-launched as The Joan Gaeta Lung Cancer Fund benefiting the Addario Lung Cancer Medical Institute. Their ultimate goal remains the same: “to eradicate lung cancer.” By partnering with one significant research initiative, they can make a much greater impact in wiping out lung cancer.
www.forjoan.org
About The Addario Lung Cancer Medical Institute (ALCMI)
The Addario Lung Cancer Medical Institute (ALCMI) is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for Lung Cancer patients.
For more information Contact:
www.alcmi.net
The Addario Lung Cancer Medical Institute Launches Unique Lung Cancer Research Initiative
Innovative international research consortium's first study opens
SAN FRANCISCO, March 28, 2011 /PRNewswire-USNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI, voiced as "Alchemy") today announced the enrollment of the initial subjects into its inaugural clinical trial known as CASTLE, targeting 250 subjects over two years among academic and community medical centers in the United States. CASTLE stands for Collaborative Advanced Stage Tissue Lung Cancer study.
ALCMI is an innovative, patient-founded non-profit research consortium that facilitates and drives comprehensively contracted collaborations among researchers in academic and community medical centers with the mission of significantly increasing the currently poor survival rates of patients diagnosed with lung cancer.
Approximately 1.5 million people will be diagnosed with lung cancer in 2011, and 1.3 million will die from it, worldwide. In clear contrast to other cancers, the 5-year survival rate of lung cancer (15.5%) has not improved over the past 40 years. More people die from lung cancer than six other top cancers combined—specifically breast, colon, prostate, kidney, liver and melanoma. Among the key contributors to this lack of progress have been the disproportionally low federal investment in research and a lack of meaningful coordination of efforts against lung cancer, resulting in late diagnoses, few and only temporarily effective therapies, and broadly inconsistent standards of care.
Recognizing the imperative for a paradigm shift in the battle against lung cancer, the Bonnie J. Addario Lung Cancer Foundation (BJALCF) and leading lung cancer scientists in the U.S. and Europe co-founded ALCMI in 2008 as a standalone, results-focused research consortium. ALCMI pools knowledge, biospecimens and data so as to facilitate and accelerate the development and delivery of much more effective diagnostics and treatments tailored to the individual patient, leading as soon as possible to personalized therapies and vastly improved patient survival rates.
ALCMI has established shared infrastructures including centralized data systems and biorepositories, and has also focused efforts to include community-based physicians and hospitals. The importance is that it brings research to where the patients are most commonly treated. "Tissues from cancer surgeries are usually discarded in community hospitals once a diagnosis is made, quite literally throwing away the ability to go back to retest these tissues as new technologies and treatments emerge," explained Steven Young, President & COO of ALCMI. "CASTLE directs the collection and analysis of tissue and blood that are essential to research and the development of individually tailored therapies."
Although research studies have demonstrated that the genetic (molecular) testing of tumors can help benefit patient outcomes, only a minority of physicians routinely order these tests. "CASTLE is collecting tissue and blood samples from advanced-stage cancer patients to perform molecular tests so clinicians can make informed decisions on best available treatments, such as more effective, targeted drugs rather than nonspecific, too often ineffective and toxic chemotherapy," said David Carbone, MD, PhD, chair of ALCMI's Scientific Leadership Board. "By studying blood and tumor tissue, we can identify and test new genetic markers and detect lung cancer at a much earlier stage, with the goal of developing simple blood tests enabling interventions while the cancer cells are most vulnerable."
Bonnie Addario, advanced stage lung cancer survivor and founder of BJALCF and ALCMI, declared at the launch of CASTLE that "Empowered patients live longer. Our message is simple—we want to live!"
About the Addario Lung Cancer Medical Institute (ALCMI)
ALCMI was established in 2008 as a 501(c) (3) non-profit organization with the ultimate goal of significantly impacting survival by catalyzing and accelerating discovery of new and more effective treatment options for all lung cancer patients.
Collaborating institutions in the United States include Dana-Farber Cancer Institute (Boston, MA), Hoag Memorial Hospital Presbyterian (Newport Beach, CA), Lahey Clinic (Burlington, MA), New York University (NY, NY), University of California Davis (Sacramento, CA), University of California, San Francisco (San Francisco, CA), University of Southern California (Los Angeles, CA) and Vanderbilt University (Nashville, TN); European collaborating institutions include the Catalan Institute of Oncology (Barcelona, Spain) and University of Torino (Turin, Italy)
www.alcmi.net
About the Bonnie J. Addario Lung Cancer Foundation (BJALCF)
BJALCF was established in 2006 as a 501(c) (3) non-profit organization and has raised over five million dollars to help improve the survival and quality of life of lung cancer patients.
BJALCF is one of the largest philanthropies and recognized force devoted exclusively to eradicating lung cancer through research, early detection, education, prevention, and treatment. The Foundation works with a diverse group of physicians, organizations, industry partners, individuals, survivors, and their families to identify solutions and make timely and meaningful change.
www.lungcancerfoundation.org
SOURCE Addario Lung Cancer Medical Institute
SAN FRANCISCO, March 28, 2011 /PRNewswire-USNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI, voiced as "Alchemy") today announced the enrollment of the initial subjects into its inaugural clinical trial known as CASTLE, targeting 250 subjects over two years among academic and community medical centers in the United States. CASTLE stands for Collaborative Advanced Stage Tissue Lung Cancer study.
ALCMI is an innovative, patient-founded non-profit research consortium that facilitates and drives comprehensively contracted collaborations among researchers in academic and community medical centers with the mission of significantly increasing the currently poor survival rates of patients diagnosed with lung cancer.
Approximately 1.5 million people will be diagnosed with lung cancer in 2011, and 1.3 million will die from it, worldwide. In clear contrast to other cancers, the 5-year survival rate of lung cancer (15.5%) has not improved over the past 40 years. More people die from lung cancer than six other top cancers combined—specifically breast, colon, prostate, kidney, liver and melanoma. Among the key contributors to this lack of progress have been the disproportionally low federal investment in research and a lack of meaningful coordination of efforts against lung cancer, resulting in late diagnoses, few and only temporarily effective therapies, and broadly inconsistent standards of care.
Recognizing the imperative for a paradigm shift in the battle against lung cancer, the Bonnie J. Addario Lung Cancer Foundation (BJALCF) and leading lung cancer scientists in the U.S. and Europe co-founded ALCMI in 2008 as a standalone, results-focused research consortium. ALCMI pools knowledge, biospecimens and data so as to facilitate and accelerate the development and delivery of much more effective diagnostics and treatments tailored to the individual patient, leading as soon as possible to personalized therapies and vastly improved patient survival rates.
ALCMI has established shared infrastructures including centralized data systems and biorepositories, and has also focused efforts to include community-based physicians and hospitals. The importance is that it brings research to where the patients are most commonly treated. "Tissues from cancer surgeries are usually discarded in community hospitals once a diagnosis is made, quite literally throwing away the ability to go back to retest these tissues as new technologies and treatments emerge," explained Steven Young, President & COO of ALCMI. "CASTLE directs the collection and analysis of tissue and blood that are essential to research and the development of individually tailored therapies."
Although research studies have demonstrated that the genetic (molecular) testing of tumors can help benefit patient outcomes, only a minority of physicians routinely order these tests. "CASTLE is collecting tissue and blood samples from advanced-stage cancer patients to perform molecular tests so clinicians can make informed decisions on best available treatments, such as more effective, targeted drugs rather than nonspecific, too often ineffective and toxic chemotherapy," said David Carbone, MD, PhD, chair of ALCMI's Scientific Leadership Board. "By studying blood and tumor tissue, we can identify and test new genetic markers and detect lung cancer at a much earlier stage, with the goal of developing simple blood tests enabling interventions while the cancer cells are most vulnerable."
Bonnie Addario, advanced stage lung cancer survivor and founder of BJALCF and ALCMI, declared at the launch of CASTLE that "Empowered patients live longer. Our message is simple—we want to live!"
About the Addario Lung Cancer Medical Institute (ALCMI)
ALCMI was established in 2008 as a 501(c) (3) non-profit organization with the ultimate goal of significantly impacting survival by catalyzing and accelerating discovery of new and more effective treatment options for all lung cancer patients.
Collaborating institutions in the United States include Dana-Farber Cancer Institute (Boston, MA), Hoag Memorial Hospital Presbyterian (Newport Beach, CA), Lahey Clinic (Burlington, MA), New York University (NY, NY), University of California Davis (Sacramento, CA), University of California, San Francisco (San Francisco, CA), University of Southern California (Los Angeles, CA) and Vanderbilt University (Nashville, TN); European collaborating institutions include the Catalan Institute of Oncology (Barcelona, Spain) and University of Torino (Turin, Italy)
www.alcmi.net
About the Bonnie J. Addario Lung Cancer Foundation (BJALCF)
BJALCF was established in 2006 as a 501(c) (3) non-profit organization and has raised over five million dollars to help improve the survival and quality of life of lung cancer patients.
BJALCF is one of the largest philanthropies and recognized force devoted exclusively to eradicating lung cancer through research, early detection, education, prevention, and treatment. The Foundation works with a diverse group of physicians, organizations, industry partners, individuals, survivors, and their families to identify solutions and make timely and meaningful change.
www.lungcancerfoundation.org
SOURCE Addario Lung Cancer Medical Institute
Tuesday, February 22, 2011
The Bonnie J. Addario Lung Cancer Foundation Names Scott Santarella as New President and CEO
Former President and CEO of the American Lung Association (NY) to Lead Foundation's Worldwide Efforts
SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- The Bonnie J. Addario Lung Cancer Foundation (BJALCF), a global leader in efforts to eradicate lung cancer, today announced that it has named Scott Santarella as its new President and CEO.
Santarella, former President and CEO of the American Lung Association in New York and former COO of the Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) will step into the previous role of Bonnie J. Addario, who is now Chairman of the Board.
Mr. Santarella brings more than 20 years of experience as a senior executive with a proven track record in innovative marketing, successful management of fundraising, and raising awareness for underfunded diseases and causes. His knowledge of science and research combined with the highest regard to ethics and constituent service has driven his successful track record of raising more than $250 million in his previous leadership roles.
Prior to his senior posts at the MMRF and MMRC, Mr. Santarella was highly successful in several key roles at the Educational Foundation of America, Earthplace, Knights of Columbus and the March of Dimes Birth Defects Foundation. He graduated Cum Laude at the University of Massachusetts with a B.A. in Journalism and completed the Executive Leadership Program at Harvard Business School.
"Our foundation is enormously fortunate to have Scott take the helm," says Bonnie J. Addario, BJALCF founder and lung cancer survivor. "Not only does he bring the depth and breadth of financial and management expertise that will be instrumental in our expansion, he's a fundraising champion. He managed to lift an annual non-profit's combined revenue to 300 percent, while maintaining annual administrative expenses at seven percent. I am proud of what we've built so far, and I am honored to have Scott join our movement at this point in time. I want to see tangible change in the survival rate of lung cancer in my lifetime, and the addition of his leadership experience renews my confidence that this dream will become a reality."
"It's a real honor for me," says Scott, "to have been selected as the President and CEO of BJALCF. I admire and respect Bonnie a great deal and have been a huge fan of the foundation's innovative work and business focus. I am truly looking forward to working with the foundation's team to take the organization to the next level."
"Funding for the Number One Cancer Killer is more than forty years past due," says Sheila Von Driska, BJALCF Executive Director. "With an alarming incidence of lung cancer in never smokers on the rise, it's time to take this bully by the horn and take it down. Scott's experience is a fresh new kick-start for the second round in this worldwide battle. We look forward to letting lung cancer know it's 'game over.'"
About the Bonnie J. Addario Lung Cancer Foundation (BJALCF)
BJALCF is one of the largest philanthropies and recognized force devoted exclusively to eradicating lung cancer through research, early detection, education, prevention, and treatment. The Foundation works with a diverse group of physicians, organizations, industry partners, individuals, survivors, and their families to identify solutions and make timely and meaningful change. BJALCF was established in 2006 as a 501(c)(3) non-profit organization and has raised over five million dollars for Lung Cancer.
About the Addario Lung Cancer Medical Institute (ALCMI)
The Addario Lung Cancer Medical Institute (ALCMI) was established in 2008 as a 501(c)(3) non-profit organization with the ultimate goal of significantly impacting survival by catalyzing and accelerating discovery of new and more effective treatment options for all lung cancer patients.
SOURCE Bonnie J. Addario Lung Cancer Foundation
SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- The Bonnie J. Addario Lung Cancer Foundation (BJALCF), a global leader in efforts to eradicate lung cancer, today announced that it has named Scott Santarella as its new President and CEO.
Santarella, former President and CEO of the American Lung Association in New York and former COO of the Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) will step into the previous role of Bonnie J. Addario, who is now Chairman of the Board.
Mr. Santarella brings more than 20 years of experience as a senior executive with a proven track record in innovative marketing, successful management of fundraising, and raising awareness for underfunded diseases and causes. His knowledge of science and research combined with the highest regard to ethics and constituent service has driven his successful track record of raising more than $250 million in his previous leadership roles.
Prior to his senior posts at the MMRF and MMRC, Mr. Santarella was highly successful in several key roles at the Educational Foundation of America, Earthplace, Knights of Columbus and the March of Dimes Birth Defects Foundation. He graduated Cum Laude at the University of Massachusetts with a B.A. in Journalism and completed the Executive Leadership Program at Harvard Business School.
"Our foundation is enormously fortunate to have Scott take the helm," says Bonnie J. Addario, BJALCF founder and lung cancer survivor. "Not only does he bring the depth and breadth of financial and management expertise that will be instrumental in our expansion, he's a fundraising champion. He managed to lift an annual non-profit's combined revenue to 300 percent, while maintaining annual administrative expenses at seven percent. I am proud of what we've built so far, and I am honored to have Scott join our movement at this point in time. I want to see tangible change in the survival rate of lung cancer in my lifetime, and the addition of his leadership experience renews my confidence that this dream will become a reality."
"It's a real honor for me," says Scott, "to have been selected as the President and CEO of BJALCF. I admire and respect Bonnie a great deal and have been a huge fan of the foundation's innovative work and business focus. I am truly looking forward to working with the foundation's team to take the organization to the next level."
"Funding for the Number One Cancer Killer is more than forty years past due," says Sheila Von Driska, BJALCF Executive Director. "With an alarming incidence of lung cancer in never smokers on the rise, it's time to take this bully by the horn and take it down. Scott's experience is a fresh new kick-start for the second round in this worldwide battle. We look forward to letting lung cancer know it's 'game over.'"
About the Bonnie J. Addario Lung Cancer Foundation (BJALCF)
BJALCF is one of the largest philanthropies and recognized force devoted exclusively to eradicating lung cancer through research, early detection, education, prevention, and treatment. The Foundation works with a diverse group of physicians, organizations, industry partners, individuals, survivors, and their families to identify solutions and make timely and meaningful change. BJALCF was established in 2006 as a 501(c)(3) non-profit organization and has raised over five million dollars for Lung Cancer.
About the Addario Lung Cancer Medical Institute (ALCMI)
The Addario Lung Cancer Medical Institute (ALCMI) was established in 2008 as a 501(c)(3) non-profit organization with the ultimate goal of significantly impacting survival by catalyzing and accelerating discovery of new and more effective treatment options for all lung cancer patients.
SOURCE Bonnie J. Addario Lung Cancer Foundation
Wednesday, December 22, 2010
The Inspirational Story of Zheng Cao
ABC's Good Morning America. Wednesday, December 22nd, 2010.
Help create more stories like this one. www.NobodyDeservesIt.com
Help create more stories like this one. www.NobodyDeservesIt.com
Monday, November 15, 2010
Tuesday, November 9, 2010
Powerful Video. Please Watch.
Please take six minutes or so to watch this powerful video from the Bonnie J. Addario Lung Cancer Foundation. The Joan Gaeta Lung Cancer Fund is VERY PROUD to be an affiliate of this fine organization.
In February, we will host our fourth annual "Dancing for Joan" fund raiser to raise money for the Addario Lung Cancer Medical Institute (ALCMI).
We would love to see you there! We are also currently soliciting sponsors for the event, with very affordable sponsorhip packages starting as low as $350 and $500.
If you cannot make it, please consider a donation. NO AMOUNT IS TOO SMALL!
Learn more at www.forjoan.org, www.dancingforjoan.org, and www.nobodydeservesit.org.
Thank you for your time and consideration.
Monday, August 9, 2010
Tuesday, July 27, 2010
The Joan Gaeta Lung Cancer Foundation is now The Joan Gaeta Lung Cancer Fund
Dedicated to supporting the Addario Lung Cancer Medical Institute (www.alcmi.net).
In the fall of 2007, The Joan Gaeta Lung Cancer Foundation was created in honor of Joan to raise awareness of the disease, to educate the public, and to be an advocate for research.
Over the last three years, we have learned a great deal about lung cancer advocacy and have been honored to support several organizations that are doing great work. We are extremely grateful to all of our supporters who have donated to our cause. It is because of your generosity that we have been able to raise awareness and to fund research initiatives.
In the fall of 2007, The Joan Gaeta Lung Cancer Foundation was created in honor of Joan to raise awareness of the disease, to educate the public, and to be an advocate for research.
Over the last three years, we have learned a great deal about lung cancer advocacy and have been honored to support several organizations that are doing great work. We are extremely grateful to all of our supporters who have donated to our cause. It is because of your generosity that we have been able to raise awareness and to fund research initiatives.
While we have funded several excellent organizations and research initiatives during our first three years, our board of directors has decided that we can do the most good for the cause by focusing on one research initiative. Rather than spreading our financial commitments across various lung cancer projects, channeling our funds to one specific initiative will enable your precisous donations to go much further.
During our time as a foundation, we have been extremely fortunate to forge a close relationship with The Bonnie J. Addario Lung Cancer Foundation (BJALCF). Two years after BJALCF began, the Addario Lung Cancer Medical Institute (ALCMI) was created. It is an international, virtual lung cancer institute dedicated to accelerating the discovery, development, and delivery of new and more efficient treatment options for lung cancer patients. ALCMI connects the top thought leaders, scientists, researchers, and physicians institutions around the United States and the world. It engages community hospitals to lead and empower patients toward better treatment options. ALCMI only considers immediate, results-oriented projects or programs promising to catalyze progress through early detection, genetic testing, drug discovery and patient-focused outcomes.
The Addario Lung Cancer Medical Institute began in San Francisco. It was there that leading physicians, clinicians, scientists, researchers, representatives from pharmaceutical and biotech companies, venture capitalists, international investors, and lung cancer survivors convened at the University of California Mission Bay Conference Center.
They met for one purpose – to answer the following question:
“If money for research and development was not a barrier, and a true collaboration could be achieved, what would you do to reach a cure for lung cancer in the least amount of time and how much would it cost?”
The unanimous answer:
“We need a national lung cancer institute – an honest third-party broker – with a virtual specimen repository connecting existing biobanks and researchers world wide through a unique, real-time IT platform and better means of collaboration.”
The goal of ALCMI is to significantly improve lung cancer patient outcomes and survival. ALCMI accomplishes this by directly facilitating scientific efforts to better characterize this complex and virtually fatal disease and thus accelerate the development of new, targeted therapies that will lead to treatments tailored to the individual lung cancer patient. To this end, ALCMI works with its partners and supporters to establish a centralized, high-quality tissue/data bank, with investigators subsequently utilizing the resultant findings in ALCMI clinical trials to screen and enrich for patients who have the best chance to positively respond to the study drugs.
“There has been little to no movement in the survival rate of lung cancer in the last half century. Everyone will tell you I’m the ultimate optimist,” says board member Dr. David Jablons of UCSF, “But I really do think that in some finite period in our lifetime, especially now with ALCMI, we will see lung cancer, if not completely eradicated, dramatically changed in its onerousness and its impact on life.”
In 2009, thanks to support from our donors, we were very happy to make a donation of $15,000 to ALCMI. Today, The Joan Gaeta Lung Cancer Foundation has become The Joan Gaeta Lung Cancer Fund and is excited to announce our formal partnership with the Addario Lung Cancer Medical Institute. 85% of the net proceeds that we raise with our lung cancer fund (primarily our annual Dancing for Joangala) will now be used to support the excellent work ALCMI is doing. Remaining funds will be used in metro Atlanta for an annual awareness campaign and to sponsor a lung cancer support group.
Click here to view an exciting and informative video about ALCMI.
We sincerely thank everyone who has made generous donations to our cause and urge you to spread the word and to continue your generosity.
Subscribe to:
Posts (Atom)